Adherex Reports First Patient Enrolled In Phase 2 Study Of Eniluracil In Metastatic B

[News]

Adherex Technologies Inc. (TSX:AHX)(PINK SHEETS:ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil today announced the enrollment of the first patient in the Phase 2 clinical trial for Metastatic Breast Cancer comparing the oral regiment of Eniluracil + 5-Fluorouracil (5-FU) and Leucovorin versus Capecitabine (Xeloda®)...

More... (http://www.medicalnewstoday.com/articles/224062.php)